Kaketsuken, also known as the Chemo-Sero-Therapeutic Research Institute, has become the first Japanese pharmaceutical company to use the combined capabilities of the Medidata Balance and Medidata Rave for a Japanese clinical trial.
The company will use the Medidata Solutions (MDSO) platform in phase II clinical trial to test a vaccine.
The Medidata's integrated solutions are expected to drive trial efficiencies and help Kaketsuken to meet trial timelines.
Kaketsuken clinical development department deputy general manager Shinji Tochihara said Medidata Rave and Balance as an integrated solution for randomization, dispensation and EDC are essential to meet trial deadlines.
"In addition, an effective support team that understands our challenges and is willing to partner with us at every step makes a remarkable difference. Medidata offers us that full package," Tochihara added.
The company also used Medidata's integrated eLearning capabilities to get sites up and running quickly.
Medidata Solutions president Glen de Vries said, "Medidata's cloud-based platform is designed to bring efficiency improvements throughout the trial process, and offers additional benefits with the use of multiple integrated applications."
